Showing results (251-260 of 792) with videos related to

Sort By:
Pageof 80
The Journal of Infectious Diseases|April 25, 2001
Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapyW Huang, V De Gruttola, M Fischl, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2012
Probing chelation motifs in HIV integrase inhibitorsArpita Agrawal, Jamie DeSoto, Jessica L Fullagar, et al.
Neurology|February 1, 1993
2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patientsA R Berger, J C Arezzo, H H Schaumburg, et al.
Molecular Diagnosis & Therapy|February 12, 2019
Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal CancerHersh A Ham-Karim, Henry Okuchukwu Ebili, Kirsty Manger, et al.
Archives of Neurology|July 1, 1988
Acquired immunodeficiency syndrome. Magnetic resonance patterns of brain involvement with pathologic correlationJ G Jarvik, J R Hesselink, C Kennedy, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|December 24, 1997
Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197M A Fischl, D D Richman, M Saag, et al.
Journal of Virology|January 15, 2005
Semen-specific genetic characteristics of human immunodeficiency virus type 1 envSatish K Pillai, Benjamin Good, Sergei Kosakovsky Pond, et al.
AIDS (London, England)|June 6, 2000
Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapyT R O'Brien, D H McDermott, J P Ioannidis, et al.
Topics in Antiviral Medicine|December 14, 2011
2011 update of the drug resistance mutations in HIV-1Victoria A Johnson, Vincent Calvez, Huldrych F Günthard, et al.
The Journal of Infectious Diseases|May 1, 1989
The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic markerS A Spector, C Kennedy, J A McCutchan, et al.
Pageof 80